AACR Press Conference Highlights Combination Potential of Two Cyclacel Drugs

AACR Press Conference Highlights Combination Potential of Two Cyclacel Drugs

Novel Drug Combination Active in Patients With Incurable BRCA-Deficient

WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.
(Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced
that the American Association of Cancer Research (AACR) highlighted data at a
press conference in Washington, D.C. from a clinical trial evaluating a novel
combination regimen of two of the Company's orally available, experimental
drugs, sapacitabine and seliciclib. The trial enrolled patients with an
incurable form of cancer associated with BRCA defects in the patients' genome.
The press conference was held yesterday on the occasion of the American
Association of Cancer Research (AACR) Annual Meeting 2013 which opened here
this weekend.

"We are pleased to have our data with sapacitabine and seliciclib selected by
the AACR's Annual Meeting Program Committee," said Spiro Rombotis, Cyclacel's
President and Chief Executive Officer. "Our novel, all-oral, combination of
two Cyclacel drugs fits the theme of this year's AACR: 'Personalizing Cancer
Care Through Discovery Science'. This recognition of the importance of our
work attests to the quality of Cyclacel's scientists and pipeline.Together
with our late-stage clinical trial of sapacitabine in elderly patients with
newly diagnosed acute myeloid leukemia, these promising data in patients with
solid tumors suggest the emergence of a personalized medicine strategy for
Cyclacel in an area of high unmet medical need."

The press conference highlighted a small number of data presentations selected
from approximately 6,000 scientific presentations at the conference by
investigators from around the globe. Among the selected data, AACR previewed
promising results of the sapacitabine and seliciclib regimen. The regimen was
used to treat patients with incurable BRCA-deficient cancers.There are no
drugs yet approved specifically for this patient population.

At the press conference the principal investigator of the study, Geoffrey
Shapiro, M.D., Director, Early Drug Development Center, Dana-Farber Cancer
Institute and Associate Professor, Department of Medicine, Harvard Medical
School, announced that when given sequentially, sapacitabine and seliciclib,
worked together to induce durable partial responses and prolonged stable
disease in patients who carry a BRCA mutation. The complete data will be
formally presented by Dr. Shapiro during the scientific session of the AACR on
Tuesday, April 9, at 2 pm Eastern.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target
the various phases of cell cycle control for the treatment of cancer and other
serious diseases. Sapacitabine, Cyclacel's most advanced product candidate, is
the subject of SEAMLESS, a Phase 3 trial being conducted under an SPA with the
FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly,
and other studies for myelodysplastic syndromes (MDS), chronic lymphocytic
leukemia (CLL) and solid tumors including breast, lung, ovarian and pancreatic
cancer. Cyclacel's strategy is to build a diversified biopharmaceutical
business focused in hematology and oncology based on a development pipeline of
novel drug candidates. Please visit www.cyclacel.com for additional

Forward-looking Statements

This news release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy, safety and
intended utilization of Cyclacel's product candidates, the conduct and results
of future clinical trials, plans regarding regulatory filings, future research
and clinical trials and plans regarding partnering activities. Factors that
may cause actual results to differ materially include the risk that product
candidates that appeared promising in early research and clinical trials do
not demonstrate safety and/or efficacy in larger-scale or later clinical
trials, trials may have difficulty enrolling, Cyclacel may not obtain approval
to market its product candidates, the risks associated with reliance on
outside financing to meet capital requirements, and the risks associated with
reliance on collaborative partners for further clinical trials, development
and commercialization of product candidates. You are urged to consider
statements that include the words "may," "will," "would," "could," "should,"
"believes," "estimates," "projects," "potential," "expects," "plans,"
"anticipates," "intends," "continues," "forecast," "designed," "goal," or the
negative of those words or other comparable words to be uncertain and
forward-looking. For a further list and description of the risks and
uncertainties the Company faces, please refer to our most recent Annual Report
on Form 10-K and other periodic and other filings we file with the Securities
and Exchange Commission and are available at www.sec.gov. Such forward-looking
statements are current only as of the date they are made, and we assume no
obligation to update any forward-looking statements, whether as a result of
new information, future events or otherwise.

© Copyright 2013 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The
Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. 

CONTACT: Investors/Media: Corey Sohmer,
         (908) 517-7330, csohmer@cyclacel.com

Cyclacel Pharmaceuticals logo
Press spacebar to pause and continue. Press esc to stop.